Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABBDABF 43 EV-to-OCF is 14.46 as of Aug. 28, 2026, which is 34% below its 10-year median of 21.82. GuruFocus rates BDABF with a GF Score™ of 43/100 and a GF Value™ of $15.46. The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 65.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Boule Diagnostics AB's Enterprise Value is $34.51 Mil.
Boule Diagnostics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $2.39 Mil. Therefore, Boule Diagnostics AB's EV-to-OCF for today is 14.46.
The historical rank and industry rank for Boule Diagnostics AB's EV-to-OCF or its related term are showing as below:
BDABF'
s EV-to-OCF Range Over the Past 10 Years
Min: -72.59 Med: 21.82 Max: 468.59
Current: 15.04
During the past 13 years, the highest EV-to-OCF of Boule Diagnostics AB was 468.59. The lowest was -72.59. And the median was 21.82.
BDABF's EV-to-OCF is ranked worse than 65.85% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.88
vs BDABF: 15.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boule Diagnostics AB (OTCPK:BDABF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boule Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Boule Diagnostics AB's share price for today is $7.84.
Boule Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Boule Diagnostics AB EV-to-OCF Related Terms
Boule Diagnostics AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boule Diagnostics AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's EV-to-OCF falls into.
Boule Diagnostics AB's current Enterprise Value is $34.51 Mil.
Boule Diagnostics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (BDABF) has a EV-to-OCF of 14.46 as of Aug. 28, 2026. This is 34% below median its historical median of 21.82. According to the industry distribution chart, Boule Diagnostics AB ranks #561 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Boule Diagnostics AB's EV-to-OCF too high?
Boule Diagnostics AB's current EV-to-OCF of 14.46 is 34% below median its 10-year median of 21.82. The Medical Devices & Instruments industry median EV-to-OCF is 7.88. Boule Diagnostics AB's value of 14.46 is 83.5% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #561 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #561 out of 852 companies for EV-to-OCF. This places Boule Diagnostics AB in the lower half of its industry. The industry median EV-to-OCF is 7.88. Boule Diagnostics AB's value of 14.46 is 83.5% above this benchmark. While the company's 10-year median is 21.82 vs. the industry median of 7.88, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.88, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current EV-to-OCF of 14.46 is 83.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current EV-to-OCF is 14.46, which is 34% below median its own 10-year median of 21.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current EV-to-OCF of 14.46. The stock's GF Value™ is $15.46, compared to a current price of $7.84 — trading 49.3% below its estimated fair value. The current EV-to-OCF is 14.46, which is 34% below median its 10-year median of 21.82 and 83.5% above the Medical Devices & Instruments industry median of 7.88. Boule Diagnostics AB's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current EV-to-OCF is 14.46 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 49.3% below its estimated GF Value™ of $15.46.
Key valuation signals for BDABF:
EV-to-OCF: 14.46 (34% below median its 10-year median of 21.82)
GF Value™: $15.46 vs. price of $7.84 (49.3% below fair value)
Industry Position: 83.5% above the Medical Devices & Instruments median (#561 of 852)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
43GF Score
Get the complete analysis for BDABF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
